Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 410-417

  Al Ghananeem, Abeer M ^a   Malkawi, Ahmad H ^a   Muammer, Yahya M ^a   Balko, Justin M ^a   Black, Esther P ^a   Mourad, Walid ^b   Romond, Edward ^c  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Hyaluronic acid; Intratumor; Mammary tumor; Nanoparticles; Paclitaxel

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; HYALURONIC ACID; PACLITAXEL; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NANOPHARMACEUTICS; NONHUMAN; RAT; SINGLE DRUG DOSE; TUMOR VOLUME; ANIMAL; CHEMISTRY; EXPERIMENTAL NEOPLASM; SOLUBILITY; SPRAGUE DAWLEY RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; FEMALE; HYALURONIC ACID; MAMMARY NEOPLASMS, EXPERIMENTAL; NANOPARTICLES; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 67549104172     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9222-5     Document Type: Article

References (36)

1. Deurloo MJ, Kop W, van Tellingen O, Bartelink H, Begg AC. Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution. Cancer Chemother Pharmacol 1991;27 5:347-53.
2. Aigner KR. Intra-arterial infusion: Overview and novel approaches. Semin Surg Oncol 1998;14 3:248-53.
3. Lee JD, Yang WI, Lee MG. Effective local control of malignant melanoma by intratumoural injection of a beta-emitting radionuclide. Eur J Nucl Med Mol Imaging 2002;29 2:221-30.
4. Zhang X, Jackson JK, Wong W. Development of biodegradable polymeric paste formulations for taxol: An in vitro and in vivo study. Inter J Pharm 1996;137 2:199-208.
5. Dhanikula AB, Panchagnula R. Development and characterization of biodegradable chitosan films for local delivery of paclitaxel. AAPS J 2004;6 3:e 27.
6. Ho EA, Vassileva V, Allen C, Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implants system for the sustained delivery of paclitaxel. J Cont Rel 2005;104 1:181-91.
7. Ramaswamy M, Zhang X, Burt HM, Wasan KM. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 1997;86 4:460-4.
8. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999;10 5:755-63.
9. Lokeshwar VB, Selzer MG. Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells. J Biol Chem 2000;275 36:27641-9.
10. Obara K, Ishihara M, Ozeki Y. Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice. J Control Release 2005;110 1:79-89.
11. Hardingham T, Fosang A. Proteoglycans: Many forms and many functions. FASEB J 1992;6 3:861-70.
12. Hoare K, Savani RC, Wang C, Yang B, Turley EA. Identification of hyaluronan binding proteins using a biotinylated hyaluronan probe. Connect Tissue Res 1993;30 2:117-26.
13. Turley EA, Belch AJ, Poppema AJ, Pilarski LM. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant lymphocytes-B. Blood 1993;81 2:446-53.
14. Vazquez E, Dewitt DM, Hammond PT, Lynn DM. Construction of hydrolytically-degradable thin films via layer-by-layer deposition of degradable polyelectrolytes. J Am Chem Soc 2002;124 47:13992-3.
15. Benkirane-Jessel N, Schwinte P, Falvey P. Build-up of polypeptide multilayer coatings with anti-inflammatory properties based on the embedding of piroxicam-cyclodextrin complexes. Adv Funct Mater 2004;14 2:174-82.
16. Guyomard A, Nysten B, Muller G, Glinel K. Loading and release of small hydrophobic molecules in multilayer films based on amphiphilic polysaccharides. Langmuir 2006;22 5:2281-7.
17. Berg MC, Zhai L, Cohen RE, Rubner MF. Controlled drug release from porous polyelectrolyte multilayers. Biomacromolecules 2006;7 1:357-64.
18. Massey PJ, Chen TT, Caudle MR. Biphasic steroidogenic effects of taxol and cremophor EL. Endocrine 1994;2 10:891-7.
19. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98 4:822-31.
20. Shu XZ, Liu Y, Palumbo FS, Prestwich GD. Disulfide-crosslinked hyaluronan-gelatin hydrogel films: A covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 2003;24 21:3825-34.
21. Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999;25 4:471-6.
22. Isik Gonul I, Akyurek N, Dursun A, Kupeli B. Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 2008;204 10:707-17.
23. Pouyani T, Prestwich GD. Functionalized derivatives of hyaluronic acid oligosaccharides: Drug carriers and novel biomaterials. Bioconjug Chem 1994;5 4:339-47.
24. Prestwich GD, Marecak DM, Marecek JF, Vercruysse KP, Ziebell MR. Controlled chemical modification of hyaluronic acid: Synthesis, applications, and biodegradation of hydrazide derivatives. J Controlled Release 1998;53 1-3:93-103.
25. Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther 1998;15 5:513-55.
26. Jaracz S, Chen J, Kuznetsova LV, Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005;13 17:5043-54.
27. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Delivery 2005;12 6:327-42.
28. Yadav AK, Mishra P, Agrawal GP. An insight on hyaluronic acid in drug targeting and drug delivery. J Drug Targ 2008;16:91-107.
29. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
30. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11 23:8230-4.
31. Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993;10 7:945-53.
32. Culty M, O'Mara TE, Underhill CB, Yeager H Jr, Swartz RP. Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages. J Leukoc Biol 1994;56 5:605-11.
33. Herrera-Gayol A, Jothy S. Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro. Int J Exp Pathol 2001;82 3:193-200.
34. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271 5252:1079-80.
35. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Inv 2002;110 4:475-82.
36. Harper E, Dang W, Lapidus RG, Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 1999;5 12:4242-8.